- Metabolic Risk/Epidemiology
-
- Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
-
Seung Joon Choi, Seong Min Kim, Yun Soo Kim, Oh Sang Kwon, Seung Kak Shin, Kyoung Kon Kim, Kiyoung Lee, Ie Byung Park, Cheol Soo Choi, Dong Hae Chung, Jaehun Jung, MunYoung Paek, Dae Ho Lee
-
Diabetes Metab J. 2021;45(5):739-752. Published online October 28, 2020
-
DOI: https://doi.org/10.4093/dmj.2020.0137
-
-
9,553
View
-
228
Download
-
16
Web of Science
-
17
Crossref
-
 Graphical Abstract
 Abstract
 PDF Supplementary Material PubReader  ePub
 - Background
Several noninvasive tools are available for the assessment of nonalcoholic fatty liver disease (NAFLD) including clinical and blood biomarkers, transient elastography (TE), and magnetic resonance imaging (MRI) techniques, such as proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE). In the present study, we aimed to evaluate whether magnetic resonance (MR)-based examinations better discriminate the pathophysiologic features and fibrosis progression in NAFLD than other noninvasive methods.
Methods
A total of 133 subjects (31 healthy volunteers and 102 patients with NAFLD) were subjected to clinical and noninvasive NAFLD evaluation, with additional liver biopsy in some patients (n=54).
Results
MRI-PDFF correlated far better with hepatic fat measured by MR spectroscopy (r=0.978, P<0.001) than with the TE controlled attenuation parameter (CAP) (r=0.727, P<0.001). In addition, MRI-PDFF showed stronger correlations with various pathophysiologic parameters for cellular injury, glucose and lipid metabolism, and inflammation, than the TE-CAP. The MRI-PDFF and TE-CAP cutoff levels associated with abnormal elevation of serum alanine aminotransferase were 9.9% and 270 dB/m, respectively. The MRE liver stiffness measurement (LSM) showed stronger correlations with liver enzymes, platelets, complement component 3, several clinical fibrosis scores, and the enhanced liver fibrosis (ELF) score than the TE-LSM. In an analysis of only biopsied patients, MRE performed better in discriminating advanced fibrosis with a cutoff value of 3.9 kPa than the TE (cutoff 8.1 kPa) and ELF test (cutoff 9.2 kPa).
Conclusion
Our results suggest that MRI-based assessment of NAFLD is the best non-invasive tool that captures the histologic, pathophysiologic and metabolic features of the disease.
-
Citations
Citations to this article as recorded by  - A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study
Zi-Ming An, Qiao-Hong Liu, Xin-Jian Ye, Qian Zhang, Hua-Fu Pei, Xin Xin, Jie Yuan, Qian Huang, Kun Liu, Fang Lu, Zhi-Han Yan, Yu Zhao, Yi-Yang Hu, Ming-Hua Zheng, Qin Feng
Clinical and Translational Gastroenterology.2024; 15(3): e00680. CrossRef - Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort
Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
Journal of Hepatology.2024;[Epub] CrossRef - A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
Diabetes & Metabolism Journal.2024; 48(4): 740. CrossRef - Imaging Methods Applicable in the Diagnostics of Alzheimer’s Disease, Considering the Involvement of Insulin Resistance
Petra Hnilicova, Ema Kantorova, Stanislav Sutovsky, Milan Grofik, Kamil Zelenak, Egon Kurca, Norbert Zilka, Petra Parvanovova, Martin Kolisek
International Journal of Molecular Sciences.2023; 24(4): 3325. CrossRef - Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages
Miguel D. Ferrer, Clara Reynés, Margalida Monserrat-Mesquida, Magdalena Quetglas-Llabrés, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A. Tur, Antoni Sureda, Antoni Pons
Antioxidants.2023; 12(3): 711. CrossRef - An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
Jia-xu Liang, Javier Ampuero, Hao Niu, Kento Imajo, Mazen Noureddin, Jaideep Behari, Dae Ho Lee, Richard L. Ehman, Fredrik Rorsman, Johan Vessby, Juan R. Lacalle, Ferenc E. Mózes, Michael Pavlides, Quentin M. Anstee, Stephen A. Harrison, Javier Castell, R
Journal of Hepatology.2023; 79(3): 592. CrossRef - Relationship between controlled attenuated parameter and magnetic resonance imaging–proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD
Ziming An, Qiaohong Liu, Wenli Zeng, Yan Wang, Qian Zhang, Huafu Pei, Xin Xin, Shuohui Yang, Fang Lu, Yu Zhao, Yiyang Hu, Qin Feng
Hepatology Communications.2022; 6(8): 1975. CrossRef - Noninvasive imaging of hepatic dysfunction: A state-of-the-art review
Ting Duan, Han-Yu Jiang, Wen-Wu Ling, Bin Song
World Journal of Gastroenterology.2022; 28(16): 1625. CrossRef - Diagnosis and Pathogenesis of Sarcopenia in Chronic Liver Disease Using Liver Magnetic Resonance Imaging
Atsushi Nakamura, Tsubasa Yoshimura, Tomomi Sato, Takeshi Ichikawa
Cureus.2022;[Epub] CrossRef - Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
International Journal of Molecular Sciences.2022; 23(9): 5035. CrossRef - Contribution of a genetic risk score to ethnic differences in fatty liver disease
Maddie J. Kubiliun, Jonathan C. Cohen, Helen H. Hobbs, Julia Kozlitina
Liver International.2022; 42(10): 2227. CrossRef - Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
Biomedicines.2022; 10(7): 1669. CrossRef - Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025
Zeitschrift für Gastroenterologie.2022; 60(09): e733. CrossRef - Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
E. Roeb, A. Canbay, H. Bantel, J. Bojunga, J. de Laffolie, M. Demir, U. W. Denzer, A. Geier, W. P. Hofmann, C. Hudert, T. Karlas, M. Krawczyk, T. Longerich, T. Luedde, M. Roden, J. Schattenberg, M. Sterneck, A. Tannapfel, P. Lorenz, F. Tacke
Zeitschrift für Gastroenterologie.2022; 60(09): 1346. CrossRef - Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal
Dorotea Bozic, Kristian Podrug, Ivana Mikolasevic, Ivica Grgurevic
Diagnostics.2022; 12(10): 2287. CrossRef - Significance of liver fat loss in chronic liver disease: Usefulness of hepatic proton density fat fraction measurement by magnetic resonance imaging in evaluating malnutrition
Atsushi Nakamura, Haruka Okada, Tsubasa Yoshimura, Manami Deguchi, Yuei Hosokawa, Tomomi Satoh, Takeshi Ichikawa, Keiji Okuyama, Yoshihiro Yoshioka, Hitoshi Asakura
Kanzo.2021; 62(9): 525. CrossRef - Screening for nonalcoholic fatty liver disease-when, who and how?
Christoph G Dietrich, Monika Rau, Andreas Geier
World Journal of Gastroenterology.2021; 27(35): 5803. CrossRef
|
KDA
